Home
1
NEWS
2
COVID-19 research
3
Antigens for SARS-CoV-2 research4
https://www.ancell-bio.com.tw/en/ Ancell Technology Inc.
Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan
The SARS-CoV-2 pandemic is transitioning into a new phase. Besides long-term effects after infection, researchers are monitoring emerging SARS-CoV-2 variants and their impact on the antiviral immune response as well as vaccine performance.Miltenyi Biotec stands committed to support these studies. We continuously develop new products adjusted to emerging SARS-CoV-2 variants. Furthermore, we provide tools and protocols that are ideally suited for working with infectious material.B cellsSARS-CoV-2 specific B cells and antibodiesT cellsSolutions for stimulation, enrichment, and analysis of rare virus-specific T cellsNK cellsFast isolation and subsequent expansion of NK cellsMyeloid cellsEnrichment and culture of myeloid cells for immunogenicity assays and study of inflammationMACS® Cell Culture and StimulationSARS-CoV-2 PepTivator® Peptide Pools – Virus-specific T cell stimulation – APC loadingMACS® Cell Culture and StimulationAntigens for SARS-CoV-2 research – Investigate virus-specific B cells and antibodiesMACS AntibodiesRecombinant antibodies for immunophenotyping during COVID-19 researchExosomesExosome research solutions for infectious diseases https://www.ancell-bio.com.tw/en/hot_396599.html SARS-CoV-2 research solutions: Helping researchers in their work on viral threats 2025-04-07 2026-04-07
Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan https://www.ancell-bio.com.tw/en/hot_396599.html
Ancell Technology Inc. 9F, No.74, Songde Rd., Xinyi Dist., Taipei City 110, Taiwan https://www.ancell-bio.com.tw/en/hot_396599.html
https://schema.org/EventMovedOnline https://schema.org/OfflineEventAttendanceMode
2025-04-07 http://schema.org/InStock TWD 0 https://www.ancell-bio.com.tw/en/hot_396599.html

Links:https://www.miltenyibiotec.com/SG-en/lp/recombinant-antigens ...

6528afd34b0e0d3f8aaa16e2dd87daeb.JPG

SARS-CoV-2 antigens offer researchers the possibility to investigate virus-specific immune responses, including antigen-specific B cells and antibodies.

All our antigens for SARS-CoV-2 research are available in different filling sizes and with or without biotinylation. Recombinantly expressed antigens are tagged with His and AviTag™.

Applications of SARS-CoV-2 antigens:

  • Detection of patient-derived antibodies
  • Characterization of patient-specific immune responses
  • Detection and phenotyping of virus-specific B cells
  • Enrichment of virus-specific B cells
  • Analysis of virus binding to host cells
  • Protein detection assays

Schematic overview of our antigens for SARS-CoV-2 research:

This overview illustrates major structural SARS-CoV-2 proteins: The spike protein (S), the nucleoprotein (N), the envelope protein (E), and the membrane protein (M). The spike protein consists of three spike monomers, which form a homotrimeric structure (spike trimer) on the SARS-CoV-2 surface. Each spike monomer consists of an S1 and an S2 subunit, connected at the furin cleavage site. During viral fusion, the receptor binding domain (RBD) binds the host cell target receptor ACE2, whereas the S2 domain mediates membrane fusion.
We offer various antigens based on the structural SARS-CoV-2 proteins as well as the target receptor ACE2.
e9249c14e35e6d25a6baae4d1949eeb3.png

Overview of our antigens for SARS-CoV-2 research:

f775ad60eb892de05d9ae9e559e04d4d.png

Order no.Sequence PartSourceTagBiotinylatedSize (μg)
Antigens for SARS-CoV-2 research
Recombinant Human ACE2     
130-127-516Q18 to S740 HEKHis, AviTag™No100
130-127-456No25
130-127-465YES50
130-127-442YES10
130-127-466Q18 to D615Insect cellsNo100
130-127-444No25
130-127-464YES50
130-127-468  YES10
spike      
Recombinant SARS-CoV-2 Spike-Trimer (HEK) 
130-127-683HEKHis, AviTag™NO50
130-127-684V16 to K1211   (K986P, V987P, RRAR682–685GSAG), with T4 fibritin trimerization motif  NO10
130-127-685YES25
Recombinant SARS-CoV-2 Spike-Prot (HEK)
130-127-680V16 to K1211   HEKHis, AviTag™NO50
130-127-681(K986P, V987P, RRAR682–685GSAG) NO10
130-127-682YES25
Furin cleavage site
(and control) 
     
SARS-CoV-2 Furin Cleavage Site and SARS-CoV-2 Furin Cleavage Site Control
130-127-689S673 to S691 (RRAR) Yes 100
130-127-690Yes (FAM-biotin) 100
130-127-691S673 to S691 (RRAR682–685GSAG)YES100
130-127-692Yes (FAM-biotin) 100
Receptor binding domain     
Recombinant SARS-CoV-2 RBD
130-127-518R319 to S591HEKHis, AviTag™No100
130-127-448No25
130-127-457YES50
130-127-458YES10
130-127-453Insect cellsNo100
130-127-463No25
130-127-469YES50
130-127-445YES10
S domain  
Recombinant SARS-CoV-2 Spike-S1 (HEK)       
130-127-854V16  to P681 HEKHis, AviTag™ NO50
130-127-852NO10
130-127-853YES25
Recombinant SARS-CoV-2 Spike-S2
(insect cells)
    
130-127-686S686 to K1211 (K986P, V987P)Insect cellsHis, AviTag™ NO50
130-127-687NO10
130-127-688YES25
 nucleoprotein 
Recombinant SARS-CoV-2 Nucleoprotein     
130-127-517Full length   
130-127-462S2 to A419 HEKHis, AviTag™ NO50
130-127-467NO10
130-127-454   YES25
envelope protein      
SARS-CoV-2 envelope antigens     
130-127-446(Region:C-terminus) L34 to V75NO100
130-127-451YES100
130-127-455(Region:N-terminus) M1 to S16NO100
130-127-461YES100
130-127-450(Region:Helical segment 2 (H2)) S55 to V75NO100
130-127-452   YES100



c7c9ed6606a2a6bce2b1aea77ae56235.png

Previous Back to List Next